Barclays’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.13M | Buy |
6,727
+719
| +12% | +$169K | ﹤0.01% | 2308 |
|
|
2026
Q1 | $1.2M | Sell |
6,008
-26,974
| -82% | -$5.34M | ﹤0.01% | 2643 |
|
|
2025
Q4 | $6.24M | Buy |
32,982
+2,699
| +9% | +$519K | ﹤0.01% | 2043 |
|
|
2025
Q3 | $5.36M | Sell |
30,283
-8,698
| -22% | -$1.29M | ﹤0.01% | 2142 |
|
|
2025
Q2 | $4.43M | Buy |
38,981
+14,131
| +57% | +$1.51M | ﹤0.01% | 2232 |
|
|
2025
Q1 | $2.61M | Sell |
24,850
-15,122
| -38% | -$1.71M | ﹤0.01% | 2431 |
|
|
2024
Q4 | $4.28M | Sell |
39,972
-3,484
| -8% | -$394K | ﹤0.01% | 2294 |
|
|
2024
Q3 | $4.35M | Buy |
43,456
+7,247
| +20% | +$730K | ﹤0.01% | 2208 |
|
|
2024
Q2 | $3.05M | Buy |
36,209
+17,421
| +93% | +$1.39M | ﹤0.01% | 1847 |
|
|
2024
Q1 | $1.37M | Sell |
18,788
-14,997
| -44% | -$1.11M | ﹤0.01% | 2873 |
|
|
2023
Q4 | $2.41M | Buy |
33,785
+16,016
| +90% | +$945K | ﹤0.01% | 2766 |
|
|
2023
Q3 | $1.06M | Buy |
17,769
+3,366
| +23% | +$222K | ﹤0.01% | 2292 |
|
|
2023
Q2 | $1.04M | Sell |
14,403
-365
| -2% | -$27.4K | ﹤0.01% | 2279 |
|
|
2023
Q1 | $1.09M | Sell |
14,768
-22,555
| -60% | -$1.6M | ﹤0.01% | 2674 |
|
|
2022
Q4 | $2.49M | Sell |
37,323
-7,197
| -16% | -$468K | ﹤0.01% | 2102 |
|
|
2022
Q3 | $2.39M | Buy |
44,520
+35,502
| +394% | +$2.09M | ﹤0.01% | 1625 |
|
|
2022
Q2 | $502K | Sell |
9,018
-23,226
| -72% | -$1.32M | ﹤0.01% | 2847 |
|
|
2022
Q1 | $2.26M | Sell |
32,244
-58,893
| -65% | -$4.27M | ﹤0.01% | 1774 |
|
|
2021
Q4 | $8.78M | Buy |
91,137
+19,518
| +27% | +$1.8M | ﹤0.01% | 1335 |
|
|
2021
Q3 | $6.22M | Buy |
71,619
+21,254
| +42% | +$1.64M | ﹤0.01% | 1481 |
|
|
2021
Q2 | $4.12M | Sell |
50,365
-14,154
| -22% | -$1.18M | ﹤0.01% | 1711 |
|
|
2021
Q1 | $6.14M | Buy |
64,519
+18,415
| +40% | +$1.74M | ﹤0.01% | 1362 |
|
|
2020
Q4 | $2.86M | Sell |
46,104
-29,806
| -39% | -$1.7M | ﹤0.01% | 1959 |
|
|
2020
Q3 | $4.51M | Sell |
75,910
-36,771
| -33% | -$2.51M | ﹤0.01% | 1462 |
|
|
2020
Q2 | $7.86M | Sell |
112,681
-16
| -0% | -$1.01K | 0.01% | 1087 |
|
|
2020
Q1 | $5.11M | Sell |
112,697
-33,689
| -23% | -$1.91M | ﹤0.01% | 1447 |
|
|
2019
Q4 | $9.52M | Buy |
146,386
+24,760
| +20% | +$1.65M | 0.01% | 1438 |
|
|
2019
Q3 | $7.55M | Sell |
121,626
-27,326
| -18% | -$1.72M | ﹤0.01% | 1519 |
|
|
2019
Q2 | $10.6M | Buy |
148,952
+14,486
| +11% | +$1.07M | 0.01% | 1316 |
|
|
2019
Q1 | $10.5M | Buy |
134,466
+26,167
| +24% | +$1.98M | 0.01% | 1196 |
|
|
2018
Q4 | $9.17M | Sell |
108,299
-123,490
| -53% | -$13.2M | 0.01% | 1203 |
|
|
2018
Q3 | $39.7M | Sell |
231,789
-7,877
| -3% | -$1.19M | 0.03% | 512 |
|
|
2018
Q2 | $31M | Buy |
239,666
+199,136
| +491% | +$22.2M | 0.03% | 570 |
|
|
2018
Q1 | $4.18M | Buy |
40,530
+33,647
| +489% | +$3.33M | ﹤0.01% | 1786 |
|
|
2017
Q4 | $588K | Buy |
6,883
+5,620
| +445% | +$487K | ﹤0.01% | 3637 |
|
|
2017
Q3 | $108K | Sell |
1,263
-6,314
| -83% | -$500K | ﹤0.01% | 4877 |
|
|
2017
Q2 | $574K | Sell |
7,577
-35,326
| -82% | -$2.47M | ﹤0.01% | 3380 |
|
|
2017
Q1 | $2.83M | Buy |
42,903
+1,658
| +4% | +$109K | ﹤0.01% | 1756 |
|
|
2016
Q4 | $2.61M | Buy |
41,245
+591
| +1% | +$37.3K | ﹤0.01% | 1904 |
|
|
2016
Q3 | $2.59M | Buy |
40,654
+40,016
| +6,272% | +$2.94M | ﹤0.01% | 1778 |
|
|
2016
Q2 | $47K | Sell |
638
-13,901
| -96% | -$1.03M | ﹤0.01% | 4865 |
|
|
2016
Q1 | $971K | Buy |
14,539
+12,764
| +719% | +$776K | ﹤0.01% | 2558 |
|
|
2015
Q4 | $119K | Sell |
1,775
-7,795
| -81% | -$481K | ﹤0.01% | 4290 |
|
|
2015
Q3 | $507K | Buy |
9,570
+8,110
| +555% | +$492K | ﹤0.01% | 3330 |
|
|
2015
Q2 | $91K | Sell |
1,460
-4,405
| -75% | -$240K | ﹤0.01% | 4733 |
|
|
2015
Q1 | $280K | Buy |
5,865
+2,481
| +73% | +$95.1K | ﹤0.01% | 4095 |
|
|
2014
Q4 | $113K | Sell |
3,384
-2,722
| -45% | -$88.5K | ﹤0.01% | 5101 |
|
|
2014
Q3 | $175K | Buy |
6,106
+536
| +10% | +$17.8K | ﹤0.01% | 4860 |
|
|
2014
Q2 | $215K | Buy |
5,570
+508
| +10% | +$20.6K | ﹤0.01% | 4747 |
|
|
2014
Q1 | $211K | Buy |
5,062
+2,044
| +68% | +$85.2K | ﹤0.01% | 4743 |
|
|
2013
Q4 | $98K | Sell |
3,018
-20,761
| -87% | -$676K | ﹤0.01% | 5655 |
|
|
2013
Q3 | $638K | Buy |
23,779
+20,004
| +530% | +$563K | ﹤0.01% | 3839 |
|
|
2013
Q2 | $88K | Buy |
+3,775
| New | +$67.9K | ﹤0.01% | 5890 |
|
Other funds holding LGND
JT
CAM
Barclays's LGND Position: Q2 2026 in Review
Barclays increased its Ligand Pharmaceuticals (LGND) stake by 12% in Q2 2026, buying an estimated $169K and bringing the position to 6,727 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2308.
Barclays first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. The position peaked at $39.7M in Q3 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Barclays held 6,727 shares of Ligand Pharmaceuticals worth $2.13M as of Q2 2026.
- Barclays bought 719 Ligand Pharmaceuticals shares in Q2 2026, an estimated $169K.
- Ligand Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2308 holding.
- Barclays first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Barclays's Ligand Pharmaceuticals position peaked at $39.7M in Q3 2018.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.